KN-93 - CAS 139298-40-1
Catalog number: 139298-40-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H29ClN2O4S
Molecular Weight:
501.04
COA:
Inquire
Targets:
CaMK-II
Description:
KN-93 is a selective Ca2+/calmodulin-dependent protein kinase II inhibitor, which has been implicated in the regulation of smooth muscle contractility. CaM kinase II activation was inhibited by KN-93 pretreatment (IC50 ~1 μM). KN-93 inhibited histamine-induced tonic force maintenance, whereas early force development and MLC20 phosphorylation responses during the entire time course were unaffected. Both force development and maintenance in response to KCl were inhibited by KN-93. Rapid increases in KCl-induced MLC20 phosphorylation were also inhibited by KN-93, whereas steady-state MLC20 phosphorylation responses were unaffected. In contrast, phorbol 12,13-dibutyrate (PDBu) did not activate CaM kinase II and PDBu-stimulated force development was unaffected by KN-93. Thus KN-93 appears to target a step(s) essential for force maintenance in response to physiological stimuli, suggesting a role for CaM kinase II in regulating tonic contractile responses in arterial smooth muscle. Pharmacological activation of protein kinase C bypasses the KN-93 sensitive step.
Purity:
>98%
Synonyms:
KN 93; KN93
MSDS:
Inquire
InChIKey:
LLLQTDSSHZREGW-AATRIKPKSA-N
InChI:
InChI=1S/C26H29ClN2O4S/c1-28(17-5-6-21-9-11-23(27)12-10-21)20-22-7-3-4-8-26(22)29(18-19-30)34(31,32)25-15-13-24(33-2)14-16-25/h3-16,30H,17-20H2,1-2H3/b6-5+
Canonical SMILES:
CN(CC=CC1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC
1.Upcoming therapeutic targets in cutaneous lupus erythematous.
Klaeschen AS1, Wenzel J1. Expert Rev Clin Pharmacol. 2016 Feb 29:1-12. [Epub ahead of print]
Novel insights into molecular mechanisms have altered our understanding of the pathogenesis of autoimmune skin disorders. Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease characterized by auto-aggressive skin inflammation which histologically presents with interface dermatitis. This inflammation is driven by interferon (IFN)-regulated proinflammatory cytokines that orchestrate the B- and T-cell mediated lesional inflammation. During the last years, therapeutic strategies have focused on these players: biologicals targeting type I IFNs and their receptors as well as anti-B-cell drugs have been investigated in clinical trials with variable success. Very recently, CLE gene expression analyses revealed lesional activation of several pathways of the immune system, thus providing potential new therapeutic targets. In this article, we review the current knowledge concerning pathways and key mediators involved in the pathogenesis of cutaneous lupus erythematosus (including TLR-dependent and TLR-independent immune activation, NfkB, TBK1, PI3K, MAPK, JAK/STAT-pathway) and their inhibitors (e.
2.Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway.
Shi H1, Han Q2, Xu J1, Liu W1, Chu T3, Zhao L1. Gene. 2016 May 25;583(1):8-14. doi: 10.1016/j.gene.2016.02.039. Epub 2016 Feb 28.
Although studies have shown that Urotensin II (UII) can induce cardiomyocyte hypertrophy and UII-induced cardiomyocyte hypertrophy model has been widely used for hypertrophy research, but its precise mechanism remains unknown. Recent researches have demonstrated that UII-induced cardiomyocyte hypertrophy has a relationship with the changes of intracellular Ca(2+) concentration. Therefore, the aim of this study was to investigate the mechanisms of cardiomyocyte hypertrophy induced by UII and to explore whether the calcium/calmodulin-dependent protein kinase II (CaMKII)-mediated up-regulating of phospholamban (PLN) Thr17-phosphorylation signaling pathway contributed to UII-induced cardiomyocyte hypertrophy. Primary cultures of neonatal rat cardiomyocytes were stimulated for 48h with UII. Cell size, protein/DNA contents and intracellular Ca(2+) were determined. Phosphorylated and total forms of CaMKII, PLN and the total amount of serco/endo-plasmic reticulum ATPases (SERCA 2a) were quantified by western blot.
3.Early administration of nifedipine protects against angiotensin II-induced cardiomyocyte hypertrophy through regulating CaMKII-SERCA2a pathway and apoptosis in rat cardiomyocytes.
Luo J1, Zhang WD2, Du YM1. Cell Biochem Funct. 2016 Apr;34(3):181-7. doi: 10.1002/cbf.3177. Epub 2016 Mar 10.
The calcium channel blocker (CCB), nifedipine, is a more effective treatment for early- than late-stage cardiac hypertrophy. We investigated the effects of early- and late-stage nifedipine administration on calcium homeostasis, CaMKII (Ca(2+) /calmodulin-dependent protein kinase II) activity and apoptosis of cardiomyocytes under hypertrophic stimulation with angiotensin II (AngII). Primary rat cardiomyocytes were divided into five treatment groups: AK, AngII plus the CaMKII inhibitor, KN-93; AN-1 (early-stage), AngII plus nifedipine × 48 h; AN-2 (late-stage), AngII × 48 h, then AngII plus nifedipine × 48 h; C, untreated; and A, AngII × 48 h. The t1/2β [time required for intracellular Ca(2+) concentration ([Ca(2+) ]i) to decline to one half of the peak value] decreased; however, CaMKII and SERCA2a (sarcoplasmic reticulum Ca(2+) -ATPase 2a) activities increased in the AN-1 group compared with the AK group. In the AN-2 group compared with the AN-1 group, CaMKII activity, t1/2α [time required for [Ca(2+) ]i to increase from the bottom to one half of peak value], t1/2β, and apoptosis increased.
4.Suppression of outward K(+) currents by activating dopamine D1 receptors in rat retinal ganglion cells through PKA and CaMKII signaling pathways.
Li Q1, Wu N2, Cui P3, Gao F4, Qian WJ5, Miao Y6, Sun XH7, Wang Z8. Brain Res. 2016 Mar 15;1635:95-104. doi: 10.1016/j.brainres.2016.01.039. Epub 2016 Jan 27.
Dopamine plays an important role in regulating neuronal functions in the central nervous system by activating the specific G-protein coupled receptors. Both D1 and D2 dopamine receptors are extensively distributed in the retinal neurons. In the present study, we investigated the effects of D1 receptor signaling on outward K(+) currents in acutely isolated rat retinal ganglion cells (RGCs) by patch-clamp techniques. Extracellular application of SKF81297 (10μM), a specific D1 receptor agonist, significantly and reversibly suppressed outward K(+) currents of the cells, which was reversed by SCH23390 (10μM), a selective D1 receptor antagonist. We further showed that SKF81297 mainly suppressed the glybenclamide (Gb)- and 4-aminopyridine (4-AP)-sensitive K(+) current components, but did not show effect on the tetraethylammonium (TEA)-sensitive one. Both protein kinase A (PKA) and calcium/calmodulin-dependent protein kinase II (CaMKII) signaling pathways were likely involved in the SKF81297-induced suppression of the K(+) currents since either Rp-cAMP (10μM), a cAMP/PKA signaling inhibitor, or KN-93 (10μM), a specific CaMKII inhibitor, eliminated the SKF81297 effect.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CaMK-II Products


CAS 108334-68-5 Syntide 2

Syntide 2
(CAS: 108334-68-5)

Syntide 2, a synthetic peptide, is recognized as a substrate by Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Ki= 12 μM) and protein kinase C (Km = 11 µ...

CAS 1208123-85-6 CaMKII-IN-1

CaMKII-IN-1
(CAS: 1208123-85-6)

CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC.

CAS 176708-42-2 KN-92

KN-92
(CAS: 176708-42-2)

KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 inhibits histamine-induced aminopy...

CAS 118458-54-1 Arcyriaflavin A

Arcyriaflavin A
(CAS: 118458-54-1)

Arcyriaflavin A is a potent dual target agent of calcium/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 4 (CDK4). Its IC50 values a...

CAS 1188890-40-5 KN 93

KN 93
(CAS: 1188890-40-5)

KN 93 is an inhibitor of multifunctional Calmodulin-dependent protein kinase (CaMKII; Ki value 0.37 μM for inhibition of CaMKII phosphorylating activity). KN93 ...

CAS 1135280-28-2 KN-92 phosphate

KN-92 phosphate
(CAS: 1135280-28-2)

KN-92 is an inactive analog of the CaM kinase II inhibitor KN 93.

CAS 224579-74-2 MLCK inhibitor peptide 18

MLCK inhibitor peptide 18
(CAS: 224579-74-2)

A myosin light chain kinase (MLCK) inhibitor (IC50= 50 nM), and inhibits CaM kinase IIonly at 4000-fold higher concentrations.

CAS 1431698-47-3 KN-92 hydrochloride

KN-92 hydrochloride
(CAS: 1431698-47-3)

KN-92 is an inactive derivative of KN-93, the selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII). At concentrations up to 25 μM, KN-92 is ...

Chemical Structure

CAS 139298-40-1 KN-93

Quick Inquiry

Verification code

Featured Items